LITMIR.BIZ

Скачать книгу

group but not in the exposed groups, which suggested that the disruption of miRNA activity was due to chemical exposure. Messenger RNAs connecting with miR-200a and miR-375 in the control network only were enriched for the mammary gland development and gland morphogenesis pathways, and the effects of chemical exposure on these two miRNAs were confirmed in human breast cancer cell lines.

      Song and Ryu (2015) identified characteristic miRNA profiles of human whole blood in workers exposed to volatile organic compounds (VOCs) and compared their effectiveness to the conventionally used metabolite markers of exposure. They were able to discern each VOC (toluene, xylene, and ethylbenzene) from the control group with higher accuracy, sensitivity, and specificity than the urinary biomarkers. In a recent study, serum miRNAs were associated with polychlorinated biphenyl (PCB) exposures and environmental liver disease in a residential cohort (Cave et al. 2022). This longitudinal cohort study enrolled residents of Anniston, Alabama that exhibited PCB levels twice and three times higher than found in the average population (Pavuk et al. 2014). A miRNA panel for liver toxicity and disease was assessed, and many of the miRNAs correlated with biomarkers of disease toxicity, metabolic changes, and inflammation. In addition, some of the miRNAs also correlated with levels of PCB measured in the serum. These miRNAs included miR-122-5p, -192-5p, and -99a-5p, which have been previously established to have important roles in liver disease and can serve as accessible biomarkers of disease progression (Brunetto et al. 2014; Gjorgjieva et al. 2019; Lopez-Sanchez et al. 2021). While more work needs to be done to establish the causative reasons why miRNAs in blood are correlating with both disease biomarkers and exposure, the indication is that they may serve as biomarkers of environmental pollutant health effects that include liver cell loss, change in function, and inflammatory response.

      Application

The potential utility of miRNAs extends beyond their role as biomarkers of environmental toxicant exposure, encompassing applications in quantitative chemical risk assessment and in clinical diagnostics and therapeutics. Multiple studies have shown that the transcriptional benchmark dose modeling (BMD) of short-term chemical exposures can generate point-of-departure (POD) values or “breaking points” of chemical exposure that lead to disease or other adverse outcomes of regulatory concern. These next-generation toxicological assessments that use molecular measurements are consistent with traditional, longer-term apical endpoints and can inform the mode of action (MOA) via which the exposure imparts adverse outcomes (Lake et al. 2016; Thomas et al. 2007; Webster et al. 2015). The hepatic cell culture model, HepaRG, has been successfully leveraged for high-throughput transcriptomic studies that examine concentration–response relationships in order to predict liver injury (Ramaiahgari et al. 2019). Fewer studies have applied BMD assessments to miRNA expression levels but, because dysregulation of a small number of miRNAs can impact hundreds of gene targets, assessing miRNAs could reduce the complexity and variability associated with mRNA biomarkers. Rager et al. (2017) modeled multiple molecular endpoints from human cord blood after prenatal exposure to inorganic arsenic, including mRNA expression, protein expression, miRNA expression and DNA (CpG) methylation. They found twelve miRNAs significantly associated with exposure. The BMD values were 33 µg As/L urine (maternal exposure) for CpG methylation, 42 µg/L for miRNA, 45 µg/L for protein and 64 µg/L for mRNA. Interestingly, it was the epigenetic markers (including the miRNAs) that established the most conservative BMD values. Nevertheless, all endpoints reflected the epidemiological evidence of prenatal effects of inorganic arsenicals, all of which occurred below 100 µg/L urine. Stermer et al. (2019) used BMD-modeled miRNA sequencing reads and other small RNA molecular measurements of toxicity in rat sperm after exposure to the testicular toxicant ethylene glycol monomethyl ether (EMGE) and found them to be sensitive and predictive biomarkers of exposure. Calculations resulted in a BMD of 62 mg/kg using retained spermatid head (RSH), whereas percent miRNA resulted in a BMD of 59.2 mg/kg. A recent study in our laboratory (Chorley et al. 2020) indicated that miRNAs measured from mouse liver in response to DEHP exposure display early dose-responsive patterns linked to the predominant signaling pathway (PPARα); however, the BMD estimates based on these miRNAs were higher than for the target genes (163 vs 74 mg/kg-day). By contrast, another ongoing study sequenced miRNAs in liver tissue from B6C3F1 mice exposed to the rodent liver tumorigen furan and reported a mean miRNA BMD of 2.0 mg/kg/day, which was in close agreement with the 2-year determinations of hepatocyte cellular adenoma and human cellular carcinoma (HCA + HCC) BMD values of 2.3 mg/kg/day and more conservative than the most sensitive messenger RNA BMD of 2.8 mg/kg/day. miR-122 was also increased in the blood of treated mice (BMD 1.4 mg/kg/day). Overall, these studies indicate the potential usefulness of miRNA measurement in blood, tissue, and cell culture for quantitative risk assessment. Additional case studies are needed to examine a broad range of chemical MOA and whether the presence of these biomarkers in biofluids can consistently establish POD values reflective of cellular and tissue perturbation.

Clinical applications for miRNA biomarkers in biofluids are showing recent growth. In addition to their use in drug screening for DILI and drug-induced kidney injury (DIKI), they are finding utility as diagnostic and prognostic biomarkers for disease. A number of recent reviews have summarized the current miRNA diagnostic and therapeutic landscape (Bonneau et al. 2019; Chakraborty et al. 2021; Condrat et al. 2020; Hanna et al. 2019; Vandana Saini, 2021; Tribolet et al. 2020). These biomarkers can be used to indicate the presence of a pathology, or even the stage, progression, or genetic link of pathogenesis (Hanna et al. 2019). In certain situations, one miRNA biomarker may be sufficient to identify a health outcome; but more often a well-defined panel of miRNAs is necessary for increased diagnostic sensitivity or specificity. Despite the advantages of miRNA biomarkers for early detection, improved pathogen identification and personalized medicine, their translation from the research bench into the clinic has been slow. Many companies are successfully developing diagnostic miRNA panels and several products are already available to clinicians (Bonneau et al. 2019; Vandana Saini et al. 2021). In 2012, Rosetta Genomics in partnership with Precision Therapeutics launched miRview™ mets, a miRNA panel measuring the expression levels of sixty-four miRNAs that allow the identification of cancers of unknown or uncertain primary origin (CUPs), which account for up to 15% of newly diagnosed cancer cases in the United States every year. Interpace Diagnostics/Asuragen offers a product for the diagnosis of thyroid cancer that combines ThyraMIR^®, a miRNA classifier including the quantification of 10 miRNAs, and ThyGeNEXT^®, an oncogene panel for thyroid cancer stratification. This combination offers an interesting alternative to standard cytological evaluations, which fail to discriminate benign from malignant lesions in 15–30% of cases. In November 2018, the Blue Cross Blue Shield and the US Federal Employee Health Benefit Program agreed to include the ThyGeNEXT^®/ThyraMIR^® combined tests for their beneficiaries. TAmiRNA markets OsteomiR™, a product measuring the expression level of 19 blood-circulating miRNAs intended to calculate the risk of a first fracture in female patients with postmenopausal osteoporosis and type-2 diabetes. Similarly, TAmiRNA also provides the ThrombomiR™ panel (11 miRNAs), so as to assess platelet function in cardiovascular disease. In addition, miRNA-based therapeutics—including miRNA mimics or antagonists targeting miRNAs involved in hepatitis C, fibrosis, T-cell lymphoma, heart failure, mesothelioma, and ulcerative colitis—are in various phases of clinical trials (Vandana Saini et al. 2021).

      Challenges and Future Focus

      While there is considerable promise in the use of miRNA biomarkers in biofluids, the precise quantification of circulating miRNAs is challenging and the validation of introduced biomarkers is often unsuccessful. This is indicated by a decline in published biofluid-based miRNA biomarker research in the past couple of years, whereas between 2009 and 2015 yearly publications nearly doubled (Chorley et al. 2021a). This downward trajectory is partially attributed to technical obstacles for measuring miRNAs, some of which have been discussed in the preceding sections. Pre-analytical variables such as sample collection, processing, storage, and extraction are potential causes of inconsistency in miRNA measurements. Post-analytical challenges include the normalization of data and the interpretation of miRNA changes observed to be due to perturbation and release into biofluids. These uncertainties and challenges have inhibited full implementation in multiple sectors such as clinical, regulatory, and academic use.

      For pre-analytical steps, the standardization of

Скачать книгу